Kangmei Pharmaceutical Co., Ltd. (600518.SS)
CNY 2.58
(-0.39%)
CNY 2.58
(-0.39%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 4.87 Billion | 4.18 Billion | 4.15 Billion | 5.41 Billion | 11.44 Billion | 17.06 Billion |
| Cost of Revenue | 4.15 Billion | 3.54 Billion | 3.48 Billion | 5.22 Billion | 9.93 Billion | 11.61 Billion |
| Gross Profit | 715.07 Million | 633 Million | 666.23 Million | 185.48 Million | 1.51 Billion | 5.44 Billion |
| Operating Expenses | 628.4 Million | 1.64 Billion | -15.63 Billion | 2.09 Billion | 2.55 Billion | 2.68 Billion |
| Selling, General and Administrative Expenses | 855.44 Million | 650.74 Million | 655.67 Million | 1.09 Billion | 1.36 Billion | 1.57 Billion |
| Research and Development Expenses | 45.61 Million | 25.44 Million | 9.27 Million | 11.35 Million | 110.05 Million | 142.25 Million |
| Other Expenses | -272.65 Million | 970.6 Million | -16.29 Billion | 987.73 Million | 1.08 Billion | -15.52 Million |
| Cost and Expenses | 4.78 Billion | 5.19 Billion | -12.14 Billion | 7.32 Billion | 12.49 Billion | 14.3 Billion |
| Operating Income | 86.66 Million | -1.01 Billion | 14.49 Billion | -1.91 Billion | -1.04 Billion | 686.92 Million |
| Interest Expense | 56.15 Million | 78.89 Million | 1.02 Billion | 2.16 Billion | 2.24 Billion | 1.83 Billion |
| Income Tax Expense | 6.79 Million | 30.26 Million | 235.38 Million | 62.54 Million | 264.12 Million | 302.44 Million |
| Earnings before Tax | 110.36 Million | -2.66 Billion | 8.15 Billion | -31.03 Billion | -4.39 Billion | 672.48 Million |
| Net Income | 102.52 Million | -2.69 Billion | 7.91 Billion | -31.09 Billion | -4.65 Billion | 374.49 Million |
| Earnings Per Share Basic | 0.01 | -0.19 | 0.57 | -6.30 | -0.94 | 0.03 |
| Earnings Per Share Diluted | 0.01 | -0.19 | 0.57 | -6.30 | -0.94 | 0.03 |
| Weighted Average Shares Outstanding | 10.25 Billion | 13.86 Billion | 13.86 Billion | 4.93 Billion | 4.93 Billion | 12.35 Billion |
| Weighted Average Shares Outstanding (Diluted) | 10.25 Billion | 13.86 Billion | 13.86 Billion | 4.93 Billion | 4.93 Billion | 12.44 Billion |
| Gross Margin | 0.15 | 0.15 | 0.16 | 0.03 | 0.13 | 0.32 |
| EBIT Margin | 0.11 | -0.36 | 3.64 | -0.34 | -0.01 | 0.19 |
| Profit Margin | 0.02 | -0.64 | 1.91 | -5.75 | -0.41 | 0.02 |
| EBITDA | 536.71 Million | -1.49 Billion | 9.86 Billion | -28.06 Billion | -121.46 Million | 2.99 Billion |
| Earnings Before Tax Margin | 0.02 | -0.24 | 3.49 | -0.35 | -0.09 | 0.04 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 1.39 Billion | 1.26 Billion | 1.2 Billion | 4.87 Billion | 1.33 Billion | 1.15 Billion |
| Cost of Revenue | 1.21 Billion | 1.14 Billion | 1.02 Billion | 4.04 Billion | 1.1 Billion | 974.35 Million |
| Gross Profit | 188.28 Million | 120.16 Million | 173.33 Million | 831.85 Million | 233.39 Million | 182.76 Million |
| Operating Expenses | 277.6 Million | 136.45 Million | 233.79 Million | 786.69 Million | -85.81 Million | 280.15 Million |
| Selling, General and Administrative Expenses | 423.83 Million | 126.01 Million | 222.12 Million | - | -88.51 Million | 462.72 Million |
| Research and Development Expenses | 9.37 Million | 9.96 Million | 10.36 Million | - | 7.77 Million | 14.26 Million |
| Other Expenses | -155.6 Million | -468.99 Thousand | 75.39 Thousand | 23.7 Million | 17.13 Million | 4.67 Million |
| Cost and Expenses | 1.48 Billion | 1.27 Billion | 1.26 Billion | 4.82 Billion | 1.02 Billion | 1.25 Billion |
| Operating Income | -58.94 Million | -16.28 Million | 9.58 Million | 86.66 Million | 225.78 Million | -21.75 Million |
| Interest Expense | 2.45 Million | 3.1 Million | 2.98 Million | 56.15 Million | 46.78 Million | 3.11 Million |
| Income Tax Expense | 4.28 Million | 5.64 Million | 1.05 Million | 6.79 Million | -7.19 Million | 4.39 Million |
| Earnings before Tax | -5.72 Million | 15.15 Million | 9.66 Million | 110.36 Million | 242.91 Million | -17.07 Million |
| Net Income | -10.74 Million | 8.28 Million | 7.47 Million | 102.52 Million | 250.53 Million | -22.15 Million |
| Earnings Per Share Basic | -0.00 | 0.00 | 0.00 | - | 0.02 | -0.00 |
| Earnings Per Share Diluted | -0.00 | 0.00 | 0.00 | - | 0.02 | -0.00 |
| Weighted Average Shares Outstanding | 13.86 Billion | 13.86 Billion | 7.47 Billion | 10.25 Billion | 12.11 Billion | 13.86 Billion |
| Weighted Average Shares Outstanding (Diluted) | 13.86 Billion | 13.86 Billion | 7.47 Billion | 10.25 Billion | 12.11 Billion | 13.86 Billion |
| Gross Margin | 0.13 | 0.10 | 0.14 | 0.17 | 0.17 | 0.16 |
| EBIT Margin | -0.00 | 0.06 | -0.02 | - | 0.26 | -0.06 |
| Profit Margin | -0.01 | 0.01 | 0.01 | 0.02 | 0.19 | -0.02 |
| EBITDA | -3.26 Million | 73.79 Million | -27.04 Million | - | 353.43 Million | -73.39 Million |
| Earnings Before Tax Margin | -0.04 | -0.01 | 0.01 | 0.02 | 0.17 | -0.02 |
TOKYOPLAST
NEXNF
SPACK
ABLV
FNINF
NGD